Open Label, Randomized, Single Dose, Two-way Crossover Bioequivalence Study of Daclatasvir From Prodactariv 60 mg Film Coated Tablets (International Drug Agency for Pharmaceutical Industry (IDI), Egypt) and Clatazev 60 mg Tablets (Bristol-Myers Squibb Pharma, UK)
An open label randomized, single dose, two-way crossover bioequivalence study to determine the bioequivalence of Daclatasvir from Prodactariv 60 mg F.C.T (International Drug Agency for Pharmaceutical Industry (IDI), Egypt) and Clatazev 60 mg F.C.T (Bristol-Myers Squibb Pharma, UK) in Healthy Human Volunteers Under Fasting Condition
100 Clinical Results associated with International Drug Agency for Pharmaceutical Industry
0 Patents (Medical) associated with International Drug Agency for Pharmaceutical Industry
100 Deals associated with International Drug Agency for Pharmaceutical Industry
100 Translational Medicine associated with International Drug Agency for Pharmaceutical Industry